IMMUNE NETWORK RESEARCH (VSE:IMM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: pete meyer who wrote (42)	4/28/1997 11:21:00 PM
From: burner	of 134

Immune Network Research Ltd - News Release CTB-1 production begins for next study Immune Network Research Ltd IMM Shares issued 19970452 1997-04-25 close $0.1 Monday Apr 28 1997 News Release Mr Victor Jones reports The company has begun production of its monoclonal antibody CTB-1 for the next phase of in vivo studies with primates macaque mulata over the coming months. Earlier tests revealed that CTB-1 injection increased virus-neutralizing antibody levels in monkeys chronically infected with SHIV(IIIB). SHIV(IIIB) is a recombinant retrovirus designed to allow study of anti-HIV immune responses in macaque monkeys. The CTB-1 will be used to test whether monkeys that have developed symptoms of retrovirus-induced immunodeficiency benefit from CTB-1 injection in terms of lower virus load, lymphocyte subset normalization or longer disease free survival. The work will be carried out by Drs Sybille Muller and Heinz Kohler in collaboration with scientists at the New England Regional Primate Center and the US National Cancer Institute. If results from these next studies are favourable, the company would proceed to seek approval for clinical trials to determine if CTB-1 has beneficial effect on the immune system and on disease progression in human HIV infection. The company reported earlier that the US patent office has given notice of allowance of certain patent claims on the monoclonal antibody CTB-1 and its use in respect of HIV infection. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com ----------------------------------------------------------------- Hi Pete, I received a call toaday from Victor Jones, a director I believe, but unfortunately I was not home. I will try to contact this week if I can. Regards, Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next